文献速递瓣膜外科

孤立性二尖瓣感染性心内膜炎:影响结局的患者、疾病与手术因素

Isolated mitral valve endocarditis: Patient, disease, and surgical factors that influence outcomes.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-04-05

该研究纳入2002年1月至2020年1月447例孤立性二尖瓣感染性心内膜炎手术患者(NVE 326例,PVE 121例),采用随机森林机器学习进行多变量分析。金黄色葡萄球菌为最常见病原体。标准瓣膜修复组住院死亡0%,扩大修复组7.0%,NVE置换组4.1%,PVE再次置换组5.0%。任何修复术后1、5、10年生存率分别为91%、75%、62%,置换术后分别为86%、62%、44%。

要点

  • 447例孤立性二尖瓣感染性心内膜炎手术中,NVE 326例、PVE 121例,金黄色葡萄球菌最常见。
  • 住院死亡17例(3.8%);标准修复0%、扩大修复7.0%、NVE置换4.1%、PVE再次置换5.0%。
  • 任何修复术后1、5、10年生存率91%、75%、62%,置换术后86%、62%、44%。

核心结论

  • 针对患者和病理特点定制的孤立性二尖瓣感染性心内膜炎手术策略死亡率低且结果优良。
  • 标准瓣膜修复的表观优越性与患者特征和病理有关。
  • 肾功能衰竭是最强的死亡风险因素。
  • 在广泛破坏的情况下,扩大修复与置换相比无获益。

研究设计与样本

  • 回顾性分析2002年1月至2020年1月447例孤立性二尖瓣感染性心内膜炎手术,其中NVE 326例、PVE 121例。
  • 采用随机森林机器学习进行时间相关结局的多变量分析。

主要发现

  • 金黄色葡萄球菌为最常见致病菌。
  • NVE 326例中,标准二尖瓣修复88例(27%)、扩大修复43例(13%)、瓣膜置换195例(60%)。
  • 与NVE标准修复相比,接受其他所有手术的患者年龄更大、合并症更多、心功能更差、侵袭性疾病更多。
  • 住院死亡17例(3.8%);标准瓣膜修复后0例(0%)、扩大修复后3例(7.0%)、NVE置换后8例(4.1%)、PVE再次置换后6例(5.0%)。
  • 任何修复术后1、5、10年生存率分别为91%、75%、62%,置换术后分别为86%、62%、44%。

关键数值与推荐

  • 死亡的最重要风险因素为肾功能衰竭。
  • 风险校正后包括生存率在内的结局在所有组间相似。
  • 未校正的扩大修复结局,尤其在早期,在再感染、再干预、反流、跨瓣压差和生存率方面与置换相似或更差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objectives of this study were to investigate patient characteristics, valve pathology, bacteriology, and surgical techniques related to outcome of patients who underwent surgery for isolated native (NVE) or prosthetic (PVE) mitral valve endocarditis. METHODS: From January 2002 to January 2020, 447 isolated mitral endocarditis operations were performed, 326 for NVE and 121 for PVE. Multivariable analysis of time-related outcomes used random forest machine learning. RESULTS: Staphylococcus aureus was the most common causative organism. Of 326 patients with NVE, 88 (27%) underwent standard mitral valve repair, 43 (13%) extended repair, and 195 (60%) valve replacement. Compared with NVE with standard repair, patients who underwent all other operations were older, had more comorbidities, worse cardiac function, and more invasive disease. Hospital mortality was 3.8% (n = 17); 0 (0%) after standard valve repair, 3 (7.0%) after extended repair, 8 (4.1%) after NVE replacement, and 6 (5.0%) after PVE re-replacement. Survival at 1, 5, and 10 years was 91%, 75%, and 62% after any repair and 86%, 62%, and 44% after replacement, respectively. The most important risk factor for mortality was renal failure. Risk-adjusted outcomes, including survival, were similar in all groups. Unadjusted extended repair outcomes, particularly early, were similar or worse than replacement in terms of reinfection, reintervention, regurgitation, gradient, and survival. CONCLUSIONS: A patient- and pathology-tailored approach to surgery for isolated mitral valve endocarditis has low mortality and excellent results. Apparent superiority of standard valve repair is related to patient characteristics and pathology. Renal failure is the most powerful risk factor. In case of extensive destruction, extended repair shows no benefit over replacement.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Moore RA, Witten JC, Lowry AM, et al. Isolated mitral valve endocarditis: Patient, disease, and surgical factors that influence outcomes. J Thorac Cardiovasc Surg. 2022. PMID: 35927083. doi:10.1016/j.jtcvs.2022.01.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。